Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Georges Gemayel sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the transaction, the director now directly owns 24,090 shares of the company’s stock, valued at $722,700. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Momenta Pharmaceuticals stock opened at $29.49 on Friday. The firm’s fifty day moving average price is $33.92 and its 200-day moving average price is $30.78. The stock has a market cap of $3.47 billion, a P/E ratio of -10.53 and a beta of 1.51. Momenta Pharmaceuticals, Inc. has a fifty-two week low of $10.71 and a fifty-two week high of $39.88.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.14. The firm had revenue of $8.89 million for the quarter, compared to analysts’ expectations of $4.08 million. Momenta Pharmaceuticals had a negative net margin of 994.16% and a negative return on equity of 80.37%. On average, equities research analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.61 EPS for the current year.

Several research analysts have commented on the stock. Stifel Nicolaus reissued a “buy” rating on shares of Momenta Pharmaceuticals in a report on Wednesday, June 24th. JPMorgan Chase & Co. raised their price target on shares of Momenta Pharmaceuticals from $37.00 to $42.00 and gave the company an “overweight” rating in a report on Tuesday, June 16th. SunTrust Banks raised shares of Momenta Pharmaceuticals to a “buy” rating in a report on Thursday, June 18th. Cantor Fitzgerald raised their price target on shares of Momenta Pharmaceuticals from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Tuesday, June 16th. They noted that the move was a valuation call. Finally, HC Wainwright raised their price target on shares of Momenta Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $43.44.

Several institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. raised its position in Momenta Pharmaceuticals by 31.2% in the 4th quarter. Victory Capital Management Inc. now owns 15,148 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 3,606 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Momenta Pharmaceuticals by 45.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 636,481 shares of the biotechnology company’s stock valued at $12,558,000 after purchasing an additional 197,524 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Momenta Pharmaceuticals by 6.8% during the 4th quarter. Bank of New York Mellon Corp now owns 1,206,211 shares of the biotechnology company’s stock valued at $23,798,000 after purchasing an additional 77,313 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Momenta Pharmaceuticals during the 4th quarter valued at about $334,000. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of Momenta Pharmaceuticals by 107.1% during the 4th quarter. Cubist Systematic Strategies LLC now owns 67,225 shares of the biotechnology company’s stock valued at $1,326,000 after purchasing an additional 34,770 shares in the last quarter. Hedge funds and other institutional investors own 96.92% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Featured Story: What is a SEC Filing?

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.